With Vidaza standing firm against competitors, Pharmion Corp. is adding the Phase II anthracycline amrubicin for lung cancer to its pipeline in the $55 million net-of-cash buyout of privately held Cabrellis Pharmaceuticals Inc. (BioWorld Today)

Trimeris Inc.'s plan to shift emphasis for a tighter focus on its marketed HIV drug, Fuzeon, boosted speculation that the company is grooming for a potential acquisition, the likes of which the industry has seen several lately. (BioWorld Today)

Illumina Inc.'s plan to take over Solexa Inc. in a $600 million stock swap recalls the buyout of CyVera Corp. early last year, which provided Illumina an entry into the diagnostics field. (BioWorld Today)

Genentech Inc.'s planned takeover of Tanox Inc. for $20 per share, or $919 million - about $650 million net of cash - would end the royalty payout to Tanox on U.S. sales of the asthma drug Xolair from Genentech, which would also get the royalties Novartis AG has been providing Tanox as part of the companies' three-way deal. (BioWorld Today)

Pipex Therapeutics Inc. merged with the shell company Sheffield Pharmaceuticals Inc., disclosing at the same time positive data from the pivotal Phase III trial with its lead candidate Coprexa for Wilson's disease. (BioWorld Today)

Wyeth juiced Inovio Biomedical Corp.'s bottom line with a potential $64.5 million, nonexclusive licensing deal that gives the pharma giant rights to use MedPulser electroporation delivery technology in DNA vaccines. (BioWorld Today)